Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2008, for Bioanalytical Systems, Inc. (BASi), a smaller reporting company incorporated in Indiana. The company provides contract laboratory research services and manufactures scientific instruments for medical research. A significant event during this period was the sale of the Baltimore Clinical Pharmacology Research Unit (CPRU) on June 30, 2008, resulting in the exit from the Phase I first-in-human clinical study market and the classification of CPRU results as discontinued operations.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2008 | Nine Months Ended June 30, 2008 |
|---|---|---|
| Total Revenue | $11,447 | $32,313 |
| Gross Profit | $4,316 (37.7% margin) | $12,361 (38.3% margin) |
| Operating Income | $1,177 | $3,506 |
| Net Income from Continuing Operations | $407 | $1,426 |
| Net Loss from Discontinued Operations | $(661) | $(1,832) |
| Net Income (Loss) | $(254) | $(406) |
| Cash and Cash Equivalents | $1,045 (as of June 30, 2008) | |
| Revolving Line of Credit Balance | ||
| Available Borrowing Capacity | $3,418 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 5.4% for the quarter and 7.2% for the nine-month period compared to the prior year. Service revenue grew 1.5% (quarter) and 9.9% (nine months), driven by bioanalytical analysis. Product revenue grew 23.4% (quarter) but declined 1.9% (nine months) due to the loss of a long-term Vetronics contract.
- Profitability: While operating income from continuing operations increased, the company reported a net loss for both periods due to significant losses from discontinued operations (CPRU), including a $431 loss on disposal.
- Cost Structure: Cost of service revenue as a percentage of revenue increased to 68.8% in the quarter (from 66.4%) due to a $160 accrual for data recreation costs. Conversely, cost of product revenue decreased to 37.5% (from 44.2%) due to better absorption of manufacturing costs.
- Operating Expenses: Selling expenses rose 41.9% in the quarter due to expanded sales efforts and new hires. General and administrative expenses increased 9.7% due to UK facility expansion and stock compensation.
- Liquidity: Cash and cash equivalents decreased from $2,837 to $1,045. Net cash provided by continuing operating activities improved to $4,082 (nine months), while financing activities used $2,565, primarily to repay subordinated debt.
Guidance, Outlook, and Risks
- Discontinued Operations: The company exited the CPRU business but remains contingently liable for $800 annually through 2015 for lease obligations if the buyer fails to meet commitments.
- Tax Risks: The effective tax rate increased to 56.1% (quarter) and 49.8% (nine months) due to UK facility losses that could not offset domestic taxes. The company maintains a $362 reserve for uncertain tax positions related to state audits, which could impact future rates if resolved favorably.
- Debt Covenants: The company is subject to financial covenants regarding interest-bearing indebtedness to EBITDA and fixed charge coverage ratios. Management confirmed compliance as of June 30, 2008.
- Liquidity Outlook: Management expects to continue borrowing on the revolving credit facility to finance working capital and capital expenditures. The sale of the CPRU is expected to improve future liquidity by eliminating a historical drain on cash flows.
Investor Verification Checklist
- Verify the status of the $800 annual contingent liability regarding the CPRU lease and the buyer's performance.
- Monitor the resolution of state tax audits affecting the $362 uncertain tax position reserve.
- Assess the sustainability of bioanalytical revenue growth in West Lafayette and the UK, which drove recent service revenue increases.
- Review the impact of the lost Vetronics contract on long-term product revenue stability.
- Confirm ongoing compliance with debt covenants as the company relies on its revolving line of credit for operations.